DOCSLIB.ORG

William S. Johnson Papers

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
William S. Johnson Papers http://oac.cdlib.org/findaid/ark:/13030/kt138nf35g No online items Guide to the William S. Johnson Papers Daniel Hartwig Stanford University. Libraries.Department of Special Collections and University Archives Stanford, California October 2010 Copyright © 2015 The Board of Trustees of the Leland Stanford Junior University. All rights reserved. Note This encoded finding aid is compliant with Stanford EAD Best Practice Guidelines, Version 1.0. Guide to the William S. Johnson SC0530 1 Papers Overview Call Number: SC0530 Creator: Johnson, William S., 1913- Title: William S. Johnson papers Dates: 1940-1992 Physical Description: 60 Linear feet Summary: Papers document his teaching and research activities and include notebooks, research reports, subject files, correspondence, grant files, reprints, and slides. Language(s): The materials are in English. Repository: Department of Special Collections and University Archives Green Library 557 Escondido Mall Stanford, CA 94305-6064 Email: [email protected] Phone: (650) 725-1022 URL: http://library.stanford.edu/spc Gift of the estate of William S. Johnson, 1997. Information about Access This collection is open for research. Ownership & Copyright All requests to reproduce, publish, quote from, or otherwise use collection materials must be submitted in writing to the Head of Special Collections and University Archives, Stanford University Libraries, Stanford, California 94304-6064. Consent is given on behalf of Special Collections as the owner of the physical items and is not intended to include or imply permission from the copyright owner. Such permission must be obtained from the copyright owner, heir(s) or assigns. See: http://library.stanford.edu/depts/spc/pubserv/permissions.html. Restrictions also apply to digital representations of the original materials. Use of digital files is restricted to research and educational purposes. Cite As William S. Johnson Papers (SC0530). Department of Special Collections and University Archives, Stanford University Libraries, Stanford, Calif. Biographical/Historical Sketch Johnson, professor of chemistry at Stanford University, was generally regarded as one of the major figures in 20th-century organic chemistry. He served as head of Stanford's chemistry department from 1960 to 1969, and after resigning that post, was appointed the Jackson-Wood Professor of Chemistry which he held until he became emeritus in 1978. He died in 1995. Description of the Collection Papers document his teaching and research activities and include notebooks, research reports, subject files, correspondence, grant files, reprints, and slides. Access Terms Johnson, William S. Stanford University. Department of Chemistry. Faculty. Chemistry, Organic. Chemistry--Study and teaching. Papers Box 1, Folder 1 Student research report: Conrow Box 1, Folder 2 Student research report: Crackett Box 1, Folder 3 Student research report: Craddock Box 1, Folder 4 Student research report: Crawford Box 1, Folder 5 Student research report: Du Bois Guide to the William S. Johnson SC0530 2 Papers Papers Box 1, Folder 6 Student research report: Edington Box 1, Folder 7 Student research report: Hudrlik Box 1, Folder 8 Student research report: Kikuchi Box 1, Folder 9 Student research report: Kloek Box 1, Folder 10 Student research report: Okorie Box 1, Folder 11 Student research report: Ramezani Box 1, Folder 12 Student research report: Silverman Box 1, Folder 13 Orig. drawing for slides Box 1, Folder 14 Copies of new slides Box 1, Folder 15 Original slide drawings Box 1, Folder 16 Not for use in Cope lecture Box 1, Folder 17 Unused drawings, Cope lecture Box 1, Folder 18 Copies of slides for lectures Box 1, Folder 19 Slides, Trost Seminar Box 1, Folder 20 Paper III Final Drawings, Box 1, Folder 21 An Approach to Taxodione Involving Biomimetic Polyene Cyclization Methodology Box 1, Folder 22 Biomimetic Polyene Cyclizations. Total Synthesis of dl-19-Nor-4-pregnen-20-one. Asymmetric Induction by the Initiating Center. Box 1, Folder 23 Formation of Vinyl Halides from Vinyl Cations Generated by Acetylenic Participation in Biomimetic Polyene Cyclizations. Box 1, Folder 24 Paper II (X-ray) data and suppl. material Box 1, Folder 25 Paper I Final draft, Box 1, Folder 26 Paper IV, final draft Box 1, Folder 27 misc. papers, articles Box 1, Folder 28 Figures Box 1, Folder 29 Paper II, final draft and suppl., ready for duplication Box 1, Folder 30 Paper III, Final draft plus suppl., ready for duplication Box 1, Folder 31 Trost symposium, original drawings Box 1, Folder 32 Chenera figures Box 1, Folder 33 figures, photograph negatives Box 1, Folder 34 originals, Cope lecture Box 1, Folder 35 slides Box 1, Folder 36 slides Box 1, Folder 37 2 NSF proposals Box 1, Folder 38 Reprints of "Biomimetic Polyene Cyclizations: A Review"; other Johnson reprints Box 1, Folder 39 John Ellwott and Ray Conrow, slide material Box 1, Folder 40 Slide Material: Pfizer Vit D - Chiral Aletos talk Box 1, Folder 41 Slide Material: RPI talk Box 1, Folder 42 Drawings for slides Box 1, Folder 43 Slide material for Cortisone talk Box 1, Folder 44 Lecture at Gif: Mechanism and spironolactone synth Box 1, Folder 45 Chem 133 (1975-76): "Synthesis of Steroids" Box 1, Folder 46 Drawings: GM Grant Prop. Box 1, Folder 47 Records: Chem 223 and 225 Box 1, Folder 48 Slides for Cyclization Lecture Box 1, Folder 49 Telefer Drawings Box 1, Folder 50 Copies of Slides, 11-OH series, etc. Box 1, Folder 51 Control of Biomimetic Polyene Cyclizations (a grant proposal for NIH) Box 1, Folder 52 Student-Staff lists Box 2, Folder 1 Non-Enzymic, Biogenetic-Like Cyclization of a Tetraenic Acetal to Produce the D-Homosteroid Nucleus. Box 2, Folder 2 Acetylenic Bond Participation in Biogenetic-Like Olefinic Cyclizations in Nitroalkane Solvents. A Facile Total Synthesis of dl-Testosterone Benzoate. Box 2, Folder 3 Acetylenic Bond Participation in Biogenetic-Like Olefinic Cyclizations in Nitroalkane Solvents. Synthsis of the 17-Hydroxy-5-pregnan-20-one System. Box 2, Folder 4 Biomimetic Polyene Cyclizations. The Synthesis and Cyclization of 2-(4-Pentenyl)-2-cyclo-hexenol. Box 2, Folder 5 misc. papers Guide to the William S. Johnson SC0530 3 Papers Papers Box 2, Folder 6 Vinyl Fluoride Function as a Terminator of Biomimetic Polyene Cyclizations Leading to Steroids. Box 2, Folder 7 slides Box 2, Folder 8 Reprint of article "Approaches to the Synthesis of the Insect Juvenile Hormone..."; NSF proposal (xc); part of article "Biomimetic Polyene Cyclizations." Box 2, Folder 9 Corticoid Synthesis via Vinylic Flouride-Terminated Biomimetic Polyene Cyclizations Box 2, Folder 10 Recent Developments in Biomimetic Polyene Cyclizations Box 2, Folder 11 Harrington correspondence and blueprints re: house Box 2, Folder 12 Guest House and Driveway Box 2, Folder 13 Improved Asymmetric Total Synthesis of Corticoids via Biomimetic Polyene Cyclization Methodology Box 2, Folder 14 Biomimetic Polyene Cyclizations. Participation of the Trimethylsilylacetylenic Group and the Total synthesis of the D-Homosteroid System. Box 2, Folder 15 Direct Formation of the Steroid Nucleus by a Biometic Cylcization Box 2, Folder 16 Biomimetic Polyene Cyclizations : Angewandte Chemie Box 2, Folder 17 Biomimetic Polyene Cyclization. Trapping of the Resultant Carbocation by Internal Nucleophiles. Box 2, Folder 18 Biomimetic Polyene Cyclizations. Asymmetric Induction by a Chiral Center Remote from the Initiating Cationic Center. 11a-Methylprogesterone. Box 2, Folder 19 Biomimetic Polyene Cyclizations. Participation of the Trimethylsilylacetylenic Group as a Terminator and the Total Synthesis of a D-Homosteroid. Box 2, Folder 20 Biomimetic Polyene Cyclizations. Participation of the Methylacetylenic Terminator and Nitroalkanes. A Synthesis of Testosterone. Box 2, Folder 21 Biomimetic Polyene Cyclizations. A Review. Box 3, Folder 1 Biomimetic Polyene Cyclizations. Asymmetric Induction in the Cyclization of a Dienic Acetal. Box 3, Folder 2 Participation of the Styrene Group as a Terminator of Biomimetic Polyene Cyclizations. Formation of the trans-8-Methylhydrindane Ring Systems. Box 3, Folder 3 New Projects. Box 3, Folder 4 misc. notes and publications Box 3, Folder 5 misc. notes and publications Box 3, Folder 6 misc. notes and publications Box 3, Folder 7 Goodies Box 3, Folder 8 Biomimetic Polyene Cyclizations. How the Phenylacetylenic Compares with the Styryl Terminator in Influencing the Stereoselectivity of the Process. Box 3, Folder 9 Biomimetic Polyene Cyclizations. Synthesis of Racemic 19-Norprogesterone. Box 3, Folder 10 Biomimetic Polyene Cyclizations. Participation of the Phenylacetylenic Group as a Terminator and the Formation of C/D Cis Steroidal Products. Box 3, Folder 11 Novel Synthesis of Longifolene. Box 3, Folder 12 Stereospecific Total Synthesis of Racemic 11a-Hydroxyprogesterone via a Biomimetic Polyene Cyclization. Box 3, Folder 13 Applications of Biomimetic Polyene Cyclizations to Steroid Synthesis. Box 3, Folder 14 Cyclization of 1,3-Dimethyl-2-(trans, trans-7,11-dimethyl-3,7,11-dodecatrienyl)-2-cyclohexenol to Give the D-Homosteroid Nucleus. Box 3, Folder 15 Nonenzymic, Biogenetic-like Cyclization of a Trienic Acetal Box 3, Folder 16 Nonenzymic Biogenetic-like Cyclizations Box 3, Folder 17 Concerning the Mechanism of a Nonenzymic Biogenetic-Like Olefinic Cyclization Box 3, Folder 18 Synthesis and Cyclization of 4-(trans, trans-7,12-Dimethyl-3,7,11-tridecatrienyl)-3-methyl-2-cyclohexen-1-ol and of its Allylic Isomer. Box 3, Folder 19 Cyclization of 4-(trans-3,7-Octadienyl)-3-methyl-2-cyclohexene-1-ol and 4-(trans, trans-7-methyl-3,7,11-dodecatrienyl)3-methyl-2-cyclohexen-1-ol. Box 3, Folder 20 Cyclization of 1-Methyl-6-(trans, trans-7,11-dimethyl-3,7,11-dodecatrienyl)-2-cyclohexene-1-ol. Box 3, Folder 21 11a-hydroxyprogesterone Box 3, Folder 22 11a-hydroxy; Brinkmeyer, Uyaya Box 3, Folder 23 11-methyl progesterone Guide to the William S. Johnson SC0530 4 Papers Papers Box 3, Folder 24 11-allyl progesterone Box 3, Folder 25 Styryl Terminator--Discussion Box 3, Folder 26 11a-hydroxyprogesterone Box 3, Folder 27 Styryl Terminator--Discussion Box 3, Folder 28 11a OH progesterone Box 3, Folder 29 Stereoselective Indication etc.
Load more

Recommended publications
  • Agenda Florida Hospital Association 307 Park Lake Circle Orlando, FL July 14, 2016 @ 2:00 P.M
    The Florida Board of Nursing Controlled Substances Formulary Committee Agenda Florida Hospital Association 307 Park Lake Circle Orlando, FL July 14, 2016 @ 2:00 p.m. Doreen Cassarino, DNP, ARNP, FNP-BC, BC- ADM, FAANP - Chair Joe Baker, Jr. Executive Director Kathryn L Controlled Substances Formulary Committee Agenda July 14, 2016 @ 2:00 p.m. Committee Members: Doreen Cassarino, DNP, FNP-BC, BC-ADM, FAANP (Chair) Vicky Stone-Gale, DNP, FNP-C, MSN Jim Quinlan, DNP, ARNP Bernardo B. Fernandez, Jr., MD, MBA, FACP Joshua D. Lenchus, DO, RPh, FACP, SFHM Eduardo C. Oliveira, MD, MBA, FCCP Jeffrey Mesaros, PharmD, JD Attorney: Lee Ann Gustafson, Senior Assistant Attorney General Board Staff: Joe Baker, Jr., Executive Director Jessica Hollingsworth, Program Operations Administrator For more information regarding board meetings please visit http://floridasnursing.gov/meeting-information/ Or contact: Florida Board of Nursing 4052 Bald Cypress Way, Bin # C-02 Tallahassee, FL 32399-3252 Direct Line: (850)245-4125/Direct Fax: (850)617-6450 Email: [email protected] Call to Order Roll Call Committee Members: Doreen Cassarino, DNP, FNP-BC, BC-ADM, FAANP (Chair) Vicky Stone-Gale, DNP, FNP-C, MSN Jim Quinlan, DNP, ARNP Bernardo B. Fernandez, Jr., MD, MBA, FACP Joshua D. Lenchus, DO, RPh, FACP, SFHM Eduardo C. Oliveira, MD, MBA, FCCP Jeffrey Mesaros, PharmD, JD Attorney: Lee Ann Gustafson, Senior Assistant Attorney General Board Staff: Joe Baker, Jr., Executive Director Jessica Hollingsworth, Program Operations Administrator I. Review & Approve Minutes from June 29, 2016 Meeting II. Open Discussion A. Recommendations to the Board of Nursing for Rule Promulgation B. Reference Material 1.
    [Show full text]
  • [Application Note]
    [application note] SCREENING FOR ANABOLIC STEROIDS AND THEIR ESTERS USING HAIR ANALYZED BY GC TANDEM QUADRUPOLE MS Marie Bresson, Vincent Cirimele, Pascal Kintz, Marion Villain; Laboratoire Chemtox, Illkirch, France Timothy Jenkins, Waters Corporation, Manchester, UK Jean-Marc Joumier, Waters Corporations, St. Quentin en Yvelines, France INTRODUCTION Use of anabolic steroids was officially banned in the mid-1970s by two screening procedures were established: one, very rapid for sports authorities. The first control of anabolic steroids (particu- classic compounds; the second, milder, to test for the ester forms, larly metandienone found in Dianabol) was achieved in Montreal in that will again increase the specificity of the investigation. 1976 during the Olympic games.1 The official detection of anabolic steroid misuse in sports is based on the analysis of urine samples. However, some athletes take long- term treatment of anabolic steroids during the winter months and stop before the competition,2 or will take them for periods ranging from four to 18 weeks, alternating with drug-free periods of one month to one year.3 This is the reason why abusers can be found drug-free. Anabolic steroids are detectable in urine only two to four days after exposure, except for the ester forms. Hair specimens have been used for 20 years in toxicology to docu- ment long-term exposure in various forensic, occupational, and Figure 1. clinical situations.3 Structures of anabolic steroids Hair analysis allows an increase in the detection window (from detected by weeks to months) depending on the hair length. It allows a distinc- GC/MS/MS. tion to be made between a single or a repetitive use, and documents an estimation of consumed quantities.4-7 For this reason, doping during training and abstinence during competition can be detected by hair analysis.
    [Show full text]
  • (2013) Amendment No. 1 854809
    COMMITTEE/SUBCOMMITTEE AMENDMENT Bill No. HB 1041 (2013) Amendment No. 1 COMMITTEE/SUBCOMMITTEE ACTION ADOPTED (Y/N) ADOPTED AS AMENDED (Y/N) ADOPTED W/O OBJECTION (Y/N) FAILED TO ADOPT (Y/N) WITHDRAWN (Y/N) OTHER 1 Committee/Subcommittee hearing bill: Criminal Justice 2 Subcommittee 3 Representative Berman offered the following: 4 Amendment 5 Remove lines 18-111 and insert: 6 Section 1. Paragraphs (h), (i), (j), (k), (l), (m), and 7 (n) are added to subsection (3) of section 893.03, Florida 8 Statutes, to read: 9 893.03 Standards and schedules.—The substances enumerated 10 in this section are controlled by this chapter. The controlled 11 substances listed or to be listed in Schedules I, II, III, IV, 12 and V are included by whatever official, common, usual, 13 chemical, or trade name designated. The provisions of this 14 section shall not be construed to include within any of the 15 schedules contained in this section any excluded drugs listed 16 within the purview of 21 C.F.R. s. 1308.22, styled "Excluded 17 Substances"; 21 C.F.R. s. 1308.24, styled "Exempt Chemical 18 Preparations"; 21 C.F.R. s. 1308.32, styled "Exempted 19 Prescription Products"; or 21 C.F.R. s. 1308.34, styled "Exempt 20 Anabolic Steroid Products." 854809 - h1041-line18.docx Published On: 3/26/2013 5:54:33 PM Page 1 of 7 COMMITTEE/SUBCOMMITTEE AMENDMENT Bill No. HB 1041 (2013) Amendment No. 1 21 (3) SCHEDULE III.—A substance in Schedule III has a 22 potential for abuse less than the substances contained in 23 Schedules I and II and has a currently accepted medical use in 24 treatment in the United States, and abuse of the substance may 25 lead to moderate or low physical dependence or high 26 psychological dependence or, in the case of anabolic steroids, 27 may lead to physical damage.
    [Show full text]
  • Sex Differences in [3H]Nitrendipine Binding and Effects of Sex Steroid Hormones in Rat Cardiac and Cerebral Membranes
    In this study, we have attempted to charac terize the sex differences of calcium channels, using[ 3H]nitrendipine binding in the cardiac and cerebral membranes, and to examine the effects of sex steroid hormones on calcium channels in gonadectomized rats. Sex Differences in [3H]Nitrendipine Binding and Effects of Sex Steroid Hormones in Rat Cardiac and Cerebral Membranes Kenji ISHII, Takashi KANO and Joichi ANDO Department of Pharmacology, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki, Osaka 569, Japan Accepted October 16, 1987 Abstract-The sex differences and regulation by sex steroid hormones in calcium channels were studied by using [3H]nitrendipine binding to cardiac and cerebral membranes in 15-week old spontaneously hypertensive rats (SHRs). The maximal number of binding sites (Bmax) in the hippocampus of female SHRs increased by 24.1% over that in male SHRs. In the females, the Bmax values in the cardiac, striatal, thalamic and hippocampal membranes from ovariectomized SHRs de creased by 34.7, 29.9, 29.3 and 26.9%, respectively, compared to normal SHRs. This phenomenon, except for the hippocampus, was inhibited by estradiol but not by testosterone. In the male, the Bmax values in cardiac and cerebral membranes showed almost no changes after orchidectomy or treatment with estradiol or testosterone. After gonadectomy, the Bmax values in the cardiac, striatal and thalamic membranes of females decreased by 30.2, 33.0 and 35.6%, respectively, compared to those in males. The changes in apparent dissociation constant (KD) values were less remarkable than those in the Bmax values. These findings suggest that sex differences exist in the calcium channels of the heart, striatum, thalamus and hippocampus, and they suggest that estradiol, but not testosterone, may play a part in the regulation of the calcium channels in female SHRs.
    [Show full text]
  • Lista De Productos En Orden Alfabético
    FARMACÉUTICO QUÍMICO VETERINARIO COSMÉTICO Lista de productos en orden alfabético ALUMINIUM SULPHATE A AMBROXOL HCL AMBROXOL HCL PELLETS 25% AMIFOSTINE ABACAVIR AMILORIDE HCL ABACAVIR SULPHATE AMINACRINE HYDROCHLORIDE ACEBROPHYLLINE AMINOPHYLLINE ACEBUTOLOL HCL AMITRIPTYLINE EMBONATE ACECLOFENAC AMITRIPTYLINE HCL ACEFYLLINE AMITRIPTYLINE N OXIDE ACEFYLLINE PIPERAZINE ORAL AMLA EXTRACT ACEFYLLINE PIPERAZINE - STERILE) AMLODIPINE BESYLATE ACENOCOUMAROL (NICOUMALONE) AMLODIPINE MALEATE ACEPHATE TECHNICAL AMLODIPINE MESYLATE ACEPHYLLINE PIPERAZINE AMMONIUM ACEPIPHYLLINE / ACEPIFYLLINE AMMONIUM ACETATE ACETAMINOPHEN/PARACETAMOL AMMONIUM CHLORIDE ACID YELLOW 73 AMMONIUM DICHROMATE ACITRETIN AMMONIUM HYPOPHOSPHATE ACRIFLAVINE HYDROCHLORIDE AMMONIUM IODIDE ACRIFLAVINE NEUTRAL AMMONIUM PHOSPHATE DIBASIC ACRINOL AMMONIUM PHOSPHATE MONOBASIC ALUMINIUM OXIDE AMMONIUM SULPHATE ACTIVATED CHARCOL AMOMUM SUBULATUM ACYCLOVIR AMOXAPINE ACYCLOVIR SODIUM AMOXYCILLIN TRIHYDRATE ADAPALENE AMPICILLIN ANHYDROUS ADEFOVIR DIPIVOXIL AMPICILLIN SODIUM AND SULBACTAM SODIUM ADHATODA VASICAL LEAF AMPICILLIN SODIUM+SULBACTAMSODIUM AEGLE MARMELOUS FRUIT AMPICILLIN TRIHYDRATE AGOMELATINE AMPIROXICAM AJOWAN SEED OLEORESIN AMPRENAVIR AJOWAN OIL ANACYCLUS PYRETHRUM ALBENDAZOLE ANAGRELIDE HCL ALBUTEROL SULPHATE ANAGRELIDE HCL MONOHYDRATE GAMMA UNDECALACTONE ANASTRAZOLE ALENDRONATE SODIUM ANDROGRAPHATIS ALFUZOSIN ANDROGRAPHIS PANICULATA ALFUZOSIN HCL ANDROGRAPHOLIDE ALLIUM CEPA BULBS ANESTHETIC ETHER ALLIUM SATIVUM BULBS ANILINE HYDROCHLORIDE ALLYL HEPTANOATE ANISE OIL ALMAGATE
    [Show full text]
  • PDF File Generated From
    OCCASION This publication has been made available to the public on the occasion of the 50th anniversary of the United Nations Industrial Development Organisation. DISCLAIMER This document has been produced without formal United Nations editing. The designations employed and the presentation of the material in this document do not imply the expression of any opinion whatsoever on the part of the Secretariat of the United Nations Industrial Development Organization (UNIDO) concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries, or its economic system or degree of development. Designations such as “developed”, “industrialized” and “developing” are intended for statistical convenience and do not necessarily express a judgment about the stage reached by a particular country or area in the development process. Mention of firm names or commercial products does not constitute an endorsement by UNIDO. FAIR USE POLICY Any part of this publication may be quoted and referenced for educational and research purposes without additional permission from UNIDO. However, those who make use of quoting and referencing this publication are requested to follow the Fair Use Policy of giving due credit to UNIDO. CONTACT Please contact [email protected] for further information concerning UNIDO publications. For more information about UNIDO, please visit us at www.unido.org UNITED NATIONS INDUSTRIAL DEVELOPMENT ORGANIZATION Vienna International Centre, P.O. Box 300, 1400 Vienna, Austria Tel: (+43-1) 26026-0 · www.unido.org · [email protected] RESTRICTED DP/ID/SER.A/1544 ~.. !J January 1992 ORIGINAL: ENGLISH ESTABLISHMENT OF ADVANCED STEROIDS PRODUCTION DP/CUB/81/013 CUBA Technical report: UJUDO contract No.
    [Show full text]
  • United States Patent (19) 11 Patent Number: 6,068,830 Diamandis Et Al
    US00606883OA United States Patent (19) 11 Patent Number: 6,068,830 Diamandis et al. (45) Date of Patent: May 30, 2000 54) LOCALIZATION AND THERAPY OF FOREIGN PATENT DOCUMENTS NON-PROSTATIC ENDOCRINE CANCER 0217577 4/1987 European Pat. Off.. WITH AGENTS DIRECTED AGAINST 0453082 10/1991 European Pat. Off.. PROSTATE SPECIFIC ANTIGEN WO 92/O1936 2/1992 European Pat. Off.. WO 93/O1831 2/1993 European Pat. Off.. 75 Inventors: Eleftherios P. Diamandis, Toronto; Russell Redshaw, Nepean, both of OTHER PUBLICATIONS Canada Clinical BioChemistry vol. 27, No. 2, (Yu, He et al), pp. 73 Assignee: Nordion International Inc., Canada 75-79, dated Apr. 27, 1994. Database Biosis BioSciences Information Service, AN 21 Appl. No.: 08/569,206 94:393008 & Journal of Clinical Laboratory Analysis, vol. 8, No. 4, (Yu, He et al), pp. 251-253, dated 1994. 22 PCT Filed: Jul. 14, 1994 Bas. Appl. Histochem, Vol. 33, No. 1, (Papotti, M. et al), 86 PCT No.: PCT/CA94/00392 Pavia pp. 25–29 dated 1989. S371 Date: Apr. 11, 1996 Primary Examiner Yvonne Eyler S 102(e) Date: Apr. 11, 1996 Attorney, Agent, or Firm-Banner & Witcoff, Ltd. 87 PCT Pub. No.: WO95/02424 57 ABSTRACT It was discovered that prostate-specific antigen is produced PCT Pub. Date:Jan. 26, 1995 by non-proStatic endocrine cancers. It was further discov 30 Foreign Application Priority Data ered that non-prostatic endocrine cancers with Steroid recep tors can be stimulated with Steroids to cause them to produce Jul. 14, 1993 GB United Kingdom ................... 93.14623 PSA either initially or at increased levels.
    [Show full text]
  • Determination of Testosterone Esters in Serum by Liquid Chromatography – Tandem Mass Spectrometry (LC-MS-MS)
    Department of Physics, Chemistry and Biology Final Thesis Determination of testosterone esters in serum by liquid chromatography – tandem mass spectrometry (LC-MS-MS) Erica Törnvall Final Thesis performed at National Board of Forensic Medicine 2010-06-03 LITH-IFM-EX--10/2263--SE Department of Physics, Chemistry and Biology Linköping University 581 83 Linköping, Sweden 1 Department of Physics, Chemistry and Biology Determination of testosterone esters in serum by liquid chromatography – tandem mass spectrometry (LC-MS-MS) Erica Törnvall Final Thesis performed at National Board of Forensic Medicine 2010-06-03 Supervisors Yvonne Lood Martin Josefsson Examiner Roger Sävenhed 2 Avdelning, institution Datum Division, Department Date 2010-06-03 Chemistry Department of Physics, Chemistry and Biology Linköping University Språk Rapporttyp ISBN Language Report category Svenska/Swedish Licentiatavhandling ISRN: LITH-IFM-EX--10/2263--SE Engelska/English Examensarbete _________________________________________________________________ C-uppsats D-uppsats Serietitel och serienummer ISSN ________________ Övrig rapport Title of series, numbering ______________________________ _____________ URL för elektronisk version Titel Title Determination of testosterone esters in serum by liquid chromatography – tandem mass spectrometry (LC-MS-MS) Författare Author Erica Törnvall Sammanfattning Abstract Anabolic androgenic steroids are testosterone and its derivates. Testosterone is the most important naturally existing sex hormone for men and is used for its anabolic effects providing increased muscle mass. Testosterone is taken orally or by intramuscular injection in its ester form and are available illegally in different forms of esters. Anabolic androgenic steroids are today analyzed only in urine. To differentiate between the human natural testosterone and exogenous supply the quote natural testosterone and epitestosterone is used.
    [Show full text]
  • Full-Scan Accurate Mass Selectivity of Ultra-Performance Liquid
    Full-Scan Accurate Mass Selectivity of Ultra-Performance Liquid Chromatography Combined with Time-of-Flightand Orbitrap Mass Spectrometry in Hormone and Veterinary Drug Residue Analysis E. van der Heeft,a Y. J.C.Bolck,a B. Beumer,a A.W.J.M.Nijrolder,a A. A. M. Stolker,a and M. W. F. Nielena,b a RIKILT–Institute of Food Safety,Wageningen, The Netherlands b Wageningen University, Laboratory of Organic Chemistry,Wageningen, The Netherlands The applicability of ultra-performance liquid chromatography (UPLC) combined with full- scan accurate mass time-of-flight (TOF) and Orbitrap mass spectrometry (MS) to the analysis of hormone and veterinary drug residues was evaluated. Extracts from blank bovine hair were fortified with 14 steroid esters. UPLC-Orbitrap MS performed at a resolving power of 60,000 (FWHM) enabled the detection and accurate mass measurement (Ͻ3 ppm error) of all 14 steroid esters at low ng/g concentration level, despite the complex matrix background. A 5 ppm mass tolerance window proved to be essential to generate highlyselective reconstructed ion chromatograms (RICs) having reduced background from the hair matrix. UPLC-Orbitrap MS at a lower resolving power of 7500 and UPLC-TOFMS at mass resolving power 10,000 failed both to detect all of the steroid esters in hair extracts owing to the inability to mass resolve analyte ions from co-eluting isobaric matrix compounds. In a second application, animal feed extracts were fortified with coccidiostats drugs at levels ranging from 240 to 1900 ng/g. UPLC-Orbitrap MS conducted at a resolving power of 7500 and 60,000 and UPLC- TOFMS detected all of the analytes at the lowest investigated level.
    [Show full text]
  • Maria Nobile
    UNIVERSITÀ DEGLI STUDI DI MILANO School of Veterinary Medicine PhD course in Veterinary and Animal Sciences Class XXX Development and validation of methods for the detection of residues in unconventional and innovative matrices through LC-MS/MS analyses for safety of food of animal origin. Maria Nobile Tutor: Prof. Luca Maria Chiesa Coordinator: Prof. Fulvio Gandolfi ACADEMIC YEAR 2016/2017 1 "Foodstuffs become blood; blood becomes heart and brain, the stuff of thought and attitudes. Human fare is the basis of human culture and thought. If you want to improve the people give it, instead of declamations against sin, better food. Man is what he eats." Ludwig A. Feuerbach 2 TABLE OF CONTENTS ABSTRACT .......................................................................................................... 5 CHAPTER 1 ............................................................................................................ 7 INTRODUCTION ....................................................................................................... 8 1.1. FOOD SAFETY AND ANALYSIS OF RESIDUES ...................................................... 8 1.2. THE USE OF VETERINARY DRUGS IN BREEDING ................................................. 9 1.3 CORTICOSTEROIDS: BIOSYNTHESIS, REGULATION AND METABOLISM ................ 12 1.3.1. Therapeutic use of corticosteroids in breeding ............................... 16 1.3.2. The prednisolone case: pseudoendogenous or illicit treatment? .... 17 1.3.3. Corticosteroids and legislations .....................................................
    [Show full text]
  • United States
    Patented Feb. 22, 1938 2,109,400 UNITED STATES PATENT OFFICE 2,109,400 ESTERS OF TESTOSTERONE AND PROCESS OF MAKING SAME Karl Miescher, Riehen, near Basel, and Albert Wettstein and Caesar Scholz, Basel, Switzer land, assignors to the firm of Society of Chem ical Industry in Basle, Basel, Switzerland No Drawing. Application September 8, 1936, Se rial No. 99,856. In Switzerland October 5, 1935 16 Claims. (C. 260-106) This invention relates to the manufacture of The new esters are applicable in therapeutics. new esters of Saturated or unsaturated oxyke The following examples illustrate the inven tOnes of the type of androstane-3-one-17-ol by tion, the parts being by weight:- s treating the oxyketone with an acylating agent having more than two carbon atoms and con Eacample 1 taining in addition to the acylating group no 1 part of testosterone is dissolved in 4 parts group having a tendency to form salt or group of dry pyridine and the solution is heated with capable of conversion into a salt-forming group. 1.5 parts of propionic acid anhydride for 1% AS compared with testosterone and testoster hours at 125 C. The whole is then poured into 10 One-acetate the new esters are characterized by Water and allowed to stand for some time during their protractive effect. Esters derived from me which crystallization occurs. The crystalline 10 dium fatty acids, from propionic acid onwards, mass is filtered by suction, washed with water, have proved to have a particularly strong effi dried over phosphorous pentoxide and re-crys cacy in tests on rats.
    [Show full text]
  • Template 1..106
    CHAPTER 2018-13 Committee Substitute for Committee Substitute for House Bill No. 21 An act relating to controlled substances; creating s. 456.0301, F.S.; requiring certain boards to require certain registered practitioners to complete a specified board-approved continuing education course to obtain author- ization to prescribe controlled substances as part of biennial license renewal and before a specified date; providing course requirements; providing that the course may be offered in a distance learning format and requiring that it be included within required continuing education hours; prohibiting the Department of Health from renewing the license of a prescriber under specified circumstances; specifying a deadline for course completion; providing an exception from the course requirements for certain licensees; requiring such licensees to submit confirmation of course completion; authorizing certain boards to adopt rules; amending s. 456.072, F.S.; authorizing disciplinary action against practitioners for violating specified provisions relating to controlled substances; amending s. 456.44, F.S.; defining the term “acute pain”; requiring the applicable boards to adopt rules establishing certain guidelines for prescribing controlled substances for acute pain; providing that the failure of a prescriber to follow specified guidelines is grounds for disciplinary action; limiting opioid drug prescriptions for the treatment of acute pain to a specified period under certain circumstances; authorizing such prescrip- tions for an extended period if specified requirements are met; requiring a prescriber who prescribes an opioid drug for the treatment of pain other than acute pain to include a specific indication on the prescription; requiring a prescriber who prescribes an opioid drug for the treatment of pain related to a traumatic injury with a specified Injury Severity Score to concurrently prescribe an emergency opioid antagonist; amending ss.
    [Show full text]